A Prospective Multicentre Clinical Study of Dynamic Monitoring of Plasma ctDNA Methylation Markers to Predict Recurrence of Colorectal Cancer After Complete Resection of Peritoneal Metastases

Launched by FUDAN UNIVERSITY · Mar 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how changes in certain markers in the blood can help predict whether colorectal cancer will come back after surgery. The researchers are looking specifically at patients who have had surgery to remove peritoneal metastases, which are cancer cells that have spread to the lining of the abdomen. By analyzing blood samples taken before and after surgery, the study aims to understand if these markers can accurately indicate the likelihood of cancer recurrence, helping doctors provide better follow-up care.

To participate in this trial, individuals must be at least 18 years old and have a specific type of colorectal cancer that has been surgically treated. They should not have other active cancers and need to be able to understand the study's purpose. Participants will have their blood drawn at several points after surgery, and they will be monitored for at least two years to see how they are doing, including regular imaging tests. This study could provide important insights into how to monitor and manage colorectal cancer after surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • -1. No gender limit, age greater than 18 years old; 2, ECOG score ≤1; 3. Life expectancy ≥2 years; 4. Colorectal adenocarcinoma/mucinous adenocarcinoma/signet ring cell carcinoma confirmed by histopathology; 5, preoperative PCI score ≤20, peritoneal tumor cytoreductive surgery (CRS), surgery to achieve R0/1 resection; 6. Be able to understand the situation of this study and sign the informed consent.
• • 7. The primary colorectal cancer has undergone R0 resection, and there is no extraperitoneal metastasis (except ovary).
• Exclusion Criteria:
• • 1. Combined with primary malignant tumors of other organs (current or within the past 5 years) (excluding patients with skin basal cell carcinoma and cervical carcinoma in situ undergoing radical treatment); 2. Severe mental illness or drug abuse; 3, severe heart, lung, vascular disease can not tolerate surgery; 4. Pregnant or lactating women.